Does lithium therapy increase triglyceride levels in pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Does Lithium Increase Triglycerides in Pediatrics?

Yes, lithium therapy does increase triglyceride levels in pediatric patients, and this metabolic effect warrants monitoring during treatment.

Evidence from Research Studies

The evidence base specifically addressing lithium's effects on triglycerides in pediatric populations is limited, but available adult data and emerging pediatric research demonstrate consistent metabolic effects:

Direct Evidence of Triglyceride Elevation

A recent 2026 study in bipolar disorder patients showed that triglyceride levels increased significantly (P<0.001) after 3 months of lithium therapy 1. This same study found that HDL cholesterol decreased (P=0.001) and the Castelli Risk Index (an atherogenic marker) increased (P=0.001), indicating overall worsening of the lipid profile.

Another study examining lithium treatment (alone or combined with olanzapine) found that atherogenic lipids including triglycerides were increased with lithium treatment, with LDL-cholesterol significantly elevated particularly during lithium monotherapy 2. The authors specifically cautioned about lithium use in patients with pre-existing atherogenic conditions.

Predictive Factors

The 2026 study identified that patients with lower baseline inflammatory-nutritional reserve (measured by Prognostic Nutritional Index) were more vulnerable to developing atherogenic lipid changes, including triglyceride elevation 1. This suggests the metabolic effects are not uniform across all patients but depend on individual biological vulnerability.

Contrasting Historical Data

One older study from 1976 found no influence of long-term lithium on fasting triglycerides after 6 months of treatment 3. However, this study had only 12 patients and predates modern understanding of lithium's metabolic effects, making it less reliable than contemporary evidence.

Clinical Implications for Pediatric Practice

Monitoring Requirements

Given the documented triglyceride elevation with lithium:

  • Obtain baseline fasting lipid panel before initiating lithium in pediatric patients
  • Recheck lipids at 3 months after starting therapy, as significant changes can occur within this timeframe 1
  • Monitor more frequently in patients with baseline metabolic risk factors (obesity, family history of dyslipidemia, diabetes)
  • Consider checking inflammatory-nutritional markers (albumin, lymphocyte count) to identify vulnerable patients 1

Risk Stratification

Pediatric patients at highest risk for lithium-induced triglyceride elevation include those with:

  • Pre-existing obesity or metabolic syndrome
  • Family history of premature cardiovascular disease
  • Baseline elevated triglycerides or low HDL
  • Poor nutritional status or chronic inflammation
  • Concurrent use of other metabolically active medications (particularly atypical antipsychotics)

Management Approach

When triglycerides increase on lithium therapy:

  1. First-line intervention: Implement aggressive lifestyle modifications including dietary fat restriction, simple carbohydrate reduction, weight management, and increased physical activity 4

  2. Address secondary factors: Optimize glycemic control if diabetic, evaluate thyroid function (lithium commonly causes hypothyroidism which worsens lipids), and review concomitant medications

  3. Consider lipid-lowering therapy if triglycerides remain elevated >350 mg/dL (4 mmol/L) despite lifestyle changes, particularly if >700 mg/dL (8 mmol/L) to prevent pancreatitis 4

  4. Reassess lithium necessity: In patients with severe metabolic worsening, evaluate whether lithium's benefits (including unique anti-suicidal effects 5, 6) outweigh metabolic risks, though lithium remains highly effective for pediatric bipolar disorder

Important Caveats

The FDA label for lithium does not recommend its use in children under 12 years of age due to insufficient safety and effectiveness data 7. When used in adolescents, the metabolic monitoring becomes even more critical given the long-term cardiovascular implications of early lipid abnormalities.

The evidence suggests that metabolic adverse effects may reflect individual biological vulnerability rather than occurring uniformly across all patients 1. This means some pediatric patients will tolerate lithium metabolically while others develop early problems, making individualized monitoring essential rather than optional.

While lithium increases triglycerides, its efficacy for pediatric bipolar disorder matches newer agents, and tolerability is comparable to more commonly prescribed medications 5. The unique anti-suicidal and neuroprotective properties of lithium 5, 6 may justify its use despite metabolic concerns in carefully selected and monitored patients.

References

1
Research

Predicting Metabolic Adverse Effects of Lithium in Bipolar Disorder.

Journal of clinical psychopharmacology, 2026

6
Research

Lithium Treatment in Children and Adolescents.

Pharmacopsychiatry, 2018

Related Questions

Does lithium therapy increase triglyceride levels?
Does lithium treatment raise serum cholesterol levels?
What is the appropriate management for an 11-year-old female taking lurasidone (Latuda) 80 mg daily and lithium carbonate 450 mg twice daily who has a fasting triglyceride level of 370 mg/dL?
In a 76-year-old man with dizziness, syncope, shortness of breath, a family history of cardiovascular disease, and mildly elevated triglycerides (227 mg/dL) with otherwise normal labs, what is the next recommended evaluation and management?
For an 11-year-old female taking lurasidone (Latuda) 80 mg twice daily and lithium carbonate 450 mg twice daily who has hypertriglyceridemia, what dosing adjustments and lipid‑lowering interventions are recommended?
What are the differences between hypofractionation and hyperfractionation in radiation therapy, including their indications and typical dosing schedules?
Does lithium therapy increase triglyceride levels?
In a 45-year-old male construction worker with chronic dust and chemical exposure, a 10‑pack‑year smoking history, and clinical findings of chronic obstructive airway disease, how can frequent respiratory infections such as pneumonia develop as a complication?
For an 11-year-old female taking lurasidone (Latuda) 80 mg twice daily and lithium carbonate 450 mg twice daily who has hypertriglyceridemia, what dosing adjustments and lipid‑lowering interventions are recommended?
What is the appropriate management for an 11-year-old female taking lurasidone (Latuda) 80 mg daily and lithium carbonate 450 mg twice daily who has a fasting triglyceride level of 370 mg/dL?
When should permanent diabetes insipidus be considered after pituitary surgery?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.